Thorne HealthTech, Inc.

NasdaqGS:THRN Lagerbericht

Marktkapitalisierung: US$550.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Thorne HealthTech Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Für Thorne HealthTech wird ein Gewinn- und Umsatzwachstum von 57.2% bzw. 19.8% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 56.6% pro Jahr steigen soll.

Wichtige Informationen

57.2%

Wachstumsrate der Gewinne

56.62%

EPS-Wachstumsrate

Personal Products Gewinnwachstum33.1%
Wachstumsrate der Einnahmen19.8%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert16 Oct 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • Aug 12

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Thorne HealthTech, Inc. ( NASDAQ:THRN ) defied analyst predictions to release its second-quarter results, which were...

Recent updates

Analyseartikel • Aug 12

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Thorne HealthTech, Inc. ( NASDAQ:THRN ) defied analyst predictions to release its second-quarter results, which were...
Analyseartikel • Jun 07

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

With a price-to-earnings (or "P/E") ratio of 25.5x Thorne HealthTech, Inc. ( NASDAQ:THRN ) may be sending very bearish...
Analyseartikel • Dec 17

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...
Seeking Alpha • Sep 09

Thorne HealthTech Grows But Faces Macro Headwinds

Summary Thorne HealthTech went public in September 2021, raising approximately $70 million in a U.S. IPO. The company designs and sells wellness and nutraceutical products worldwide. THRN has produced revenue growth but faces inflationary pressures, the loss of a significant distributor in Europe and the stock may be fully valued here. I'm on Hold for THRN for the near term. A Quick Take On Thorne HealthTech Thorne HealthTech, Inc. (THRN) went public in September 2021, raising approximately $70 million in gross proceeds from an IPO that priced at $10.00 per share. The firm designs and sells wellness and nutraceutical products under its brands Thorne and Onegevity. Given the risks of continued inflationary pressures and a macroeconomic slowdown combined with a potentially fully valued stock at its current price of around $5.00 per share, I'm on Hold for THRN in the near term. Thorne HealthTech Overview New York, NY-based Thorne was founded to develop premium wellness products for consumers utilizing its Onegevity platform to discover and develop new products. The firm sells products directly and also has a product subscription program Management is headed by Chief Executive Officer Paul Jacobson, who has been with the firm since 2010 when he acquired Thorne Research and was previously co-founder of Onegevity Health, which was acquired by Thorne. THRN sells its products through a direct to consumer channel [DTC] as well as through online ecommerce sites such as Amazon, distributors and through connected health professionals. The company also gathers personalized testing data and has plans to use this information for additional services to practitioners. Thorne HealthTech's Market & Competition According to a 2021 market research report by Grand View Research, the global market for dietary supplements was an estimated $140.3 billion in 2020 and is forecast to reach $271 billion by 2028. This represents a forecast CAGR of 8.6% from 2021 to 2028. The main drivers for this expected growth are a growing consumer awareness of personal health and wellness products as well as increased R&D from product makers. Also, below is a chart showing the historical and projected future market size by ingredient for dietary supplements in the U.S.: U.S. Dietary Supplements Market (Grand View Research) Major competitive or other industry participants include: Nestle Health Science Metagenics Hims 23and Me Livongo Schrodinger SEMA4 Numerous other nutritional supplement companies Thorne HealthTech's Recent Financial Performance Total revenue by quarter has grown according to the following chart: 9 Quarter Total Revenue (Seeking Alpha) Gross profit by quarter has followed approximately the same trajectory as that of total revenue: 9 Quarter Gross Profit (Seeking Alpha) Selling, G&A expenses as a percentage of total revenue by quarter rose substantially in the most recent quarter: 9 Quarter Selling, G&A % Of Revenue (Seeking Alpha) Operating income by quarter has turned negative in Q2 2022: 9 Quarter Operating Income (Seeking Alpha) Earnings per share (Diluted) have turned into negative territory in Q2 2022: 9 Quarter Earnings Per Share (Seeking Alpha) (All data in above charts is GAAP) Since its IPO, THRN's stock price has fallen 38.4% vs. the U.S. S&P 500 index' drop of around 9.9%, as the chart below indicates: Stock Price Since IPO (Seeking Alpha) Valuation And Other Metrics For Thorne HealthTech Below is a table of relevant capitalization and valuation figures for the company: Measure [TTM] Amount Enterprise Value / Sales 1.31 Revenue Growth Rate 28.5% Net Income Margin 0.97 GAAP EBITDA % 1.8% Market Capitalization $267,930,000 Enterprise Value $272,780,000 Operating Cash Flow $1,190,000 Earnings Per Share (Fully Diluted) $0.04 (Source - Seeking Alpha) Below is an estimated DCF (Discounted Cash Flow) analysis of the firm's projected growth and earnings: Discounted Cash Flow - Thorne (GuruFocus) Assuming generous DCF parameters, the firm's shares would be valued at approximately $5.13 versus the current price of $5.01, indicating they are potentially currently fully valued, with the given earnings, growth and discount rate assumptions of the DCF. As a reference, a relevant partial public comparable would be larger firm Glanbia plc (GLAPF, GLAPY); shown below is a comparison of their primary valuation metrics: Metric Glanbia plc Thorne HealthTech Variance Enterprise Value / Sales 0.79 1.31 65.8% Revenue Growth Rate 23.7% 28.5% 20.3% Net Income Margin 5.4% 0.97 1689.7% Operating Cash Flow $104,990,000 $1,190,000 -98.9% (Source - Seeking Alpha) A full comparison of the two companies' performance metrics may be viewed here. Commentary On Thorne HealthTech In its last earnings call (Source - Seeking Alpha), covering Q2 2022's results, management highlighted improvements in its sales mix and the effect of increased prices and scale growth as offsets to inflationary pressures on its cost of sales. Notably, the firm's Pro and B2B sales channels produced strong growth year-over-year, excluding the loss of a distributor related to the conflict in Ukraine, which it estimates reduced Q2 revenue by "as much as $6.9 million."
Seeking Alpha • Aug 23

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Thorne HealthTech (NASDAQ:THRN) said its blood collection device OneDraw was certified in Japan as a medical device after being cleared by the Pharmaceutical and Medical Devices Agency (PMDA). "We appreciate the help from our partners in Japan because we believe this will create many additional opportunities to expand our relationships globally, while we continue to move forward on a similar regulatory pathway in the United States," said Thorne CEO Paul Jacobson. The company noted that OneDraw is already approved by the FDA as a class 2 medical device, and it has a European Conformity mark for supervised use by health-care professionals to collect blood samples to measure HbA1c for monitoring the long-term control of blood sugar (glucose) in diabetic individuals.
Seeking Alpha • Aug 09

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Thorne HealthTech press release (NASDAQ:THRN): Q2 Non-GAAP EPS of -$0.05 (vs. $0.22 Y/Y). Revenue of $56.1M (+30.8% Y/Y). FY22 guidance revised to net sales of $235M to $242M (vs. consensus of $247.13M) and EPS of of $0.36 to $0.39 (vs. consensus of $0.34). Shares -1.47% AH.
Seeking Alpha • Jun 05

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Nutraceutical companies will perform well during the next decade, even during a recession. DIY health trends are on the rise. Thorne HealthTech is well-positioned to benefit from these trends.
Analyseartikel • Mar 23

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Thorne HealthTech, Inc.'s ( NASDAQ:THRN ) strong earnings report was rewarded with a positive stock price move. We have...
Seeking Alpha • Jan 11

Thorne HealthTech: Good Potential At A Low Price

The market oversold Thorne shares. The company is growing at double-digit rates. It has strong positioning and enormous market potential. If marketing efficiency remains the same in the coming years, revenue will grow exponentially. This scenario is highly likely because the indicator is increasing. Despite the stage of aggressive growth, Thorne is already a profitable company. We expect the company to continue growing and improve profitability. The company is trading at a significant discount to its fair market value. PEG ratio is less than 1.

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:THRN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20254186865722
12/31/20243633461683
12/31/20232881617472
6/30/202325820-1522N/A
3/31/202324010-254N/A
12/31/202222916-135N/A
9/30/20222166-14-6N/A
6/30/20222063-51N/A
3/31/20221949-11-4N/A
12/31/2021184449N/A
9/30/2021172-1812N/A
6/30/2021162-1912N/A
3/31/2021150-32023N/A
12/31/2020138-31517N/A
12/31/2019103-22-11-8N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: THRNDas prognostizierte Gewinnwachstum (57.2% pro Jahr) liegt über der Sparquote (2.2%).

Ertrag vs. Markt: THRNDie Erträge des Unternehmens (57.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (16.8% pro Jahr).

Hohe Wachstumserträge: THRNEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: THRNDie Einnahmen des Unternehmens (19.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: THRNDie Einnahmen des Unternehmens (19.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von THRN in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2023/10/18 07:12
Aktienkurs zum Tagesende2023/10/13 00:00
Gewinne2023/06/30
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Thorne HealthTech, Inc. wird von 5 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Bryan SpillaneBofA Global Research
Susan AndersonCanaccord Genuity
Elizabeth AndersonEvercore ISI